Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 5, 2015
Pharmacy Choice - Pharmacy News - July 5, 2015

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
7/3/15 - Breathe Technologies, Inc. Announces FDA Clearance for Life2000 Ventilation System
By a News Reporter-Staff News Editor at Health& Medicine Week-- Breathe Technologies, Inc., a developer and manufacturer of medical technologies for patients with respiratory insufficiency and neuromuscular diseases, announced that the U.S. Food and Drug Administration has granted 510 clearance for its critical care Breathe Technologies Life2000...
7/3/15 - Ortho-Clinical Diagnostics, Inc. Receives FDA 510k Clearance for VITROS® Chemistry Products HbA1c Reagent Kit, an Enhanced Diabetes Testing Assay
By a News Reporter-Staff News Editor at Health& Medicine Week-- Ortho-Clinical Diagnostics, Inc. announced that the U.S. Food and Drug Administration has cleared the VITROS ® Chemistry Products HbA1c Reagent Kit to be used on the VITROS ® 5600 Integrated System, VITROS ® 4600 Chemistry System, and the VITROS ® 5,1 FS Chemistry System. The test
7/3/15 - Vertex drug gets FDA approval [Boston Herald]
July 03-- The Food and Drug Administration yesterday approved Vertex Pharmaceuticals' latest cystic fibrosis drug, offering new hope for about 8,500 of the 30,000 Americans who suffer from the life-threatening genetic disease. "I was driving home from work when the news popped up on my phone, and I started bawling; I called my dad and said,' Thank
7/2/15 - Adapt Pharma Acquires Narcan NDA and Obtains License to the Narcan® Trademark
Adapt Pharma Limited announced today that it has obtained a license to the Narcan trademark and acquired the related Narcan New Drug Application. Adapt Pharma previously announced that it had commenced a rolling submission of an NDA to the FDA for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. Use of the Narcan nam
7/2/15 - ADDING MULTIMEDIA FDA Approves ORKAMBIâ?¢ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration approved ORKAMBIâ?¢, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two
7/2/15 - FDA approves new combination pill for cystic fibrosis from Vertex Pharmaceuticals
WASHINGTON â?? Federal health officials have approved a new combination drug for the most common form of cystic fibrosis, the debilitating inherited disease that causes internal mucus buildup, lung infections and early death.

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415